Fast Afucosylation Profiling of Glycoengineered Antibody Subunits by Middle-Up Mass Spectrometry.
ADCC
Benralizumab
EndoS
EndoS2
High mannose
IdeS
Kifunensine
Low fucose
Mass spectrometry
Obinutuzumab
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
24
6
2021
Statut:
ppublish
Résumé
Middle-up LC-MS antibody characterization workflows using reduction or IdeS digestion for a focused assessment of N-glycan profiling of three representative glycoengineered monoclonal antibodies (mAbs), namely, obinutuzumab (GlycomAb technology, Glycart/Roche), benralizumab (Potelligent Technology, BioWa, Kyowa Kirin) and mAb B (kifunensine) and compared to mAb A, produced in a common CHO cell line. In addition, EndoS or EndoS2 enzyme are used for quantitative determination of Fc-glycan core afucosylation and high mannose for these antibodies, as requested by health authorities for Fc-competent therapeutics mAbs critical quality attributes (CQAs).
Identifiants
pubmed: 33908000
doi: 10.1007/978-1-0716-1241-5_5
doi:
Substances chimiques
Alkaloids
0
Antibodies, Monoclonal, Humanized
0
kifunensine
0NI8960271
benralizumab
71492GE1FX
obinutuzumab
O43472U9X8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-83Références
Beck A, Liu H (2019) Macro- and micro-heterogeneity of natural and recombinant IgG antibodies. Antibodies 8:18. https://doi.org/10.3390/antib8010018
doi: 10.3390/antib8010018
pmcid: 6640695
Duivelshof BL, Jiskoot W, Beck A, Veuthey J-L, Guillarme D, D’Atri V (2019) Glycosylation of biosimilars: recent advances in analytical characterization and clinical implications. Anal Chim Acta 1089:1–18. https://doi.org/10.1016/j.aca.2019.08.044
doi: 10.1016/j.aca.2019.08.044
pubmed: 31627805
De Leoz MLA, Duewer DL, Fung A, Liu L, Yau HK, Potter O, Staples GO, Furuki K, Frenkel R, Hu Y, Sosic Z, Zhang P, Altmann F, Nwald-Grube CG, Shao C, Zaia J, Evers W, Pengelley S, Suckau D, Wiechmann A, Resemann A, Jabs W, Beck A, Froehlich JW, Huang C, Li Y, Liu Y, Sun S, Wang Y, Seo Y, An HJ, Reichardt N-C, Ruiz JE, Archer-Hartmann S, Azadi P, Bell L, Lakos Z, An Y, Cipollo JF, Pucic-Bakovic M, Štambuk J, Lauc G, Li X, Wang PG, Bock A, Hennig R, Rapp E, Creskey M, Cyr TD, Nakano M, Sugiyama T, Leung P-KA, Link-Lenczowski P, Jaworek J, Yang S, Zhang H, Kelly T, Klapoetke S, Cao R, Kim JY, Lee HK, Lee JY, Yoo JS, Kim S-R, Suh S-K, de Haan N, Falck D, Lageveen-Kammeijer GSM, Wuhrer M, Emery RJ, Kozak RP, Liew LP, Royle L, Urbanowicz PA, Packer NH, Song X, Everest-Dass A, Lattová E, Cajic S, Alagesan K, Kolarich D, Kasali T, Lindo V, Chen Y, Goswami K, Gau B, Amunugama R, Jones R, CJM S, Kato K, Yagi H, Kondo S, Yuen CT, Harazono A, Shi X, Magnelli PE, Kasper BT, Mahal L, Harvey DJ, O’Flaherty R, Rudd PM, Saldova R, Hecht ES, Muddiman DC, Kang J, Bhoskar P, Menard D, Saati A, Merle C, Mast S, Tep S, Truong J, Nishikaze T, Sekiya S, Shafer A, Funaoka S, Toyoda M, de Vreugd P, Caron C, Pradhan P, Tan NC, Mechref Y, Patil S, Rohrer JS, Chakrabarti R, Dadke D, Lahori M, Zou C, Cairo C, Reiz B, Whittal RM, Lebrilla CB, Wu L, Guttman A, Szigeti M, Kremkow BG, Lee KH, Sihlbom C, Adamczyk B, Jin C, Karlsson NG, Örnros J, Larson G, Nilsson J, Meyer B, Wiegandt A, Komatsu E, Perreault H, Bodnar ED, Said N, Francois Y-N, Leize-Wagner E, Maier S, Zeck A, AJR H, Yang Y, Haselberg R, Yu YQ, Alley W, Leone JW, Yuan H, Stein SE (2020) NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods. Mol Cell Proteomics 19:11–30. https://doi.org/10.1074/mcp.RA119.001677
doi: 10.1074/mcp.RA119.001677
pubmed: 31591262
Beck A, Reichert JM (2012) Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 4:419–425. https://doi.org/10.4161/mabs.20996
doi: 10.4161/mabs.20996
pubmed: 22699226
pmcid: 3499336
Stoll DR, Harmes DC, Staples GO, Potter OG, Dammann CT, Guillarme D, Beck A (2018) Development of comprehensive online two-dimensional liquid chromatography/mass spectrometry using hydrophilic interaction and reversed-phase separations for rapid and deep profiling of therapeutic antibodies. Anal Chem 90:5923–5929. https://doi.org/10.1021/acs.analchem.8b00776
doi: 10.1021/acs.analchem.8b00776
pubmed: 29614857
Carter PJ, Lazar GA (2018) Next generation antibody drugs: pursuit of the “high-hanging fruit”. Nat Rev Drug Discov 17:197–223. https://doi.org/10.1038/nrd.2017.227
doi: 10.1038/nrd.2017.227
pubmed: 29192287
Capuano C, Pighi C, Maggio R, Battella S, Morrone S, Palmieri G, Santoni A, Klein C, Galandrini R (2020) CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γc cytokine stimulation via PI3K/mTOR axis. Cancer Immunol Immunother 69:501–512. https://doi.org/10.1007/s00262-020-02482-2
doi: 10.1007/s00262-020-02482-2
pubmed: 31950225
pmcid: 7113231
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJS, Poppema S, Klein C, Umaña P (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood 115:4393–4402. https://doi.org/10.1182/blood-2009-06-225979
doi: 10.1182/blood-2009-06-225979
pubmed: 20194898
pmcid: 2881503
Tai Y-T, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC (2014) Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123:3128–3138. https://doi.org/10.1182/blood-2013-10-535088
doi: 10.1182/blood-2013-10-535088
pubmed: 24569262
pmcid: 4023420
Beck A, D’Atri V, Ehkirch A, Fekete S, Hernandez-Alba O, Gahoual R, Leize-Wagner E, François Y, Guillarme D, Cianférani S (2019) Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future. Expert Rev Proteomics 16:337–362. https://doi.org/10.1080/14789450.2019.1578215
doi: 10.1080/14789450.2019.1578215
pubmed: 30706723
van der Burgt YEM, Kilgour DPA, Tsybin YO, Srzentić K, Fornelli L, Beck A, Wuhrer M, Nicolardi S (2019) Structural analysis of monoclonal antibodies by ultrahigh resolution MALDI in-source decay FT-ICR mass spectrometry. Anal Chem 91:2079–2085. https://doi.org/10.1021/acs.analchem.8b04515
doi: 10.1021/acs.analchem.8b04515
pubmed: 30571088
Largy E, Cantais F, Van Vyncht G, Beck A, Delobel A (2017) Orthogonal liquid chromatography–mass spectrometry methods for the comprehensive characterization of therapeutic glycoproteins, from released glycans to intact protein level. J Chromatogr A 1498:128–146. https://doi.org/10.1016/j.chroma.2017.02.072
doi: 10.1016/j.chroma.2017.02.072
pubmed: 28372839
D’Atri V, Nováková L, Fekete S, Stoll D, Lauber M, Beck A, Guillarme D (2019) Orthogonal middle-up approaches for characterization of the glycan heterogeneity of Etanercept by hydrophilic interaction chromatography coupled to high-resolution mass spectrometry. Anal Chem 91:873–880. https://doi.org/10.1021/acs.analchem.8b03584
doi: 10.1021/acs.analchem.8b03584
pubmed: 30512936
Ambrogelly A, Gozo S, Katiyar A, Dellatore S, Kune Y, Bhat R, Sun J, Li N, Wang D, Nowak C, Neill A, Ponniah G, King C, Mason B, Beck A, Liu H (2018) Analytical comparability study of recombinant monoclonal antibody therapeutics. MAbs 10:513–538. https://doi.org/10.1080/19420862.2018.1438797
doi: 10.1080/19420862.2018.1438797
pubmed: 29513619
pmcid: 5973765
Liu S, Zang L (2016) Rapid quantitation of monoclonal antibody N-glyco-occupancy and afucosylation using mass spectrometry. Anal Biochem 509:142–145. https://doi.org/10.1016/j.ab.2016.06.029
doi: 10.1016/j.ab.2016.06.029
pubmed: 27377969
Upton R, Bell L, Guy C, Caldwell P, Estdale S, Barran PE, Firth D (2016) Orthogonal assessment of biotherapeutic glycosylation: a case study correlating N-glycan Core Afucosylation of Herceptin with mechanism of action. Anal Chem 88:10259–10265. https://doi.org/10.1021/acs.analchem.6b02994
doi: 10.1021/acs.analchem.6b02994
pubmed: 27620140
Collin M (2001) EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J 20:3046–3055. https://doi.org/10.1093/emboj/20.12.3046
doi: 10.1093/emboj/20.12.3046
pubmed: 11406581
pmcid: 150189
Sjögren J, Struwe WB, Cosgrave EFJ, Rudd PM, Stervander M, Allhorn M, Hollands A, Nizet V, Collin M (2013) EndoS2 is a unique and conserved enzyme of serotype M49 group A streptococcus that hydrolyses N-linked glycans on IgG and α1-acid glycoprotein. Biochem J 455:107–118. https://doi.org/10.1042/BJ20130126
doi: 10.1042/BJ20130126
pubmed: 23865566
pmcid: 3778708
Sjögren J, Olsson F, Beck A (2016) Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis. Analyst 141:3114–3125. https://doi.org/10.1039/C6AN00071A
doi: 10.1039/C6AN00071A
pubmed: 27156477
Giorgetti J, Beck A, Leize-Wagner E, François Y-N (2020) Combination of intact, middle-up and bottom-up levels to characterize 7 therapeutic monoclonal antibodies by capillary electrophoresis—mass spectrometry. J Pharm Biomed Anal 182:113107. https://doi.org/10.1016/j.jpba.2020.113107
doi: 10.1016/j.jpba.2020.113107
pubmed: 32004767
Beck A, Terral G, Debaene F, Wagner-Rousset E, Marcoux J, Janin-Bussat M-C, Colas O, Dorsselaer AV, Cianférani S (2016) Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. Expert Rev Proteomics 13:157–183. https://doi.org/10.1586/14789450.2016.1132167
doi: 10.1586/14789450.2016.1132167
pubmed: 26653789
Beck A, Debaene F, Diemer H, Wagner-Rousset E, Colas O, Dorsselaer AV, Cianférani S (2015) Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies: biosimilar antibodies. J Mass Spectrom 50:285–297. https://doi.org/10.1002/jms.3554
doi: 10.1002/jms.3554
pubmed: 25800010
Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M (2007) Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17:104–118. https://doi.org/10.1093/glycob/cwl057
doi: 10.1093/glycob/cwl057
pubmed: 17012310
Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T (2008) Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99:652–665. https://doi.org/10.1002/bit.21598
doi: 10.1002/bit.21598
pubmed: 17680659
van Berkel PHC, Gerritsen J, Perdok G, Valbjørn J, Vink T, van de Winkel JGJ, Parren PWHI (2009) N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnol Prog 25:244–251. https://doi.org/10.1002/btpr.92
doi: 10.1002/btpr.92
pubmed: 19224598
Crispin M, Bowden TA, Coles CH, Harlos K, Aricescu AR, Harvey DJ, Stuart DI, Jones EY (2009) Carbohydrate and domain architecture of an immature antibody Glycoform exhibiting enhanced effector functions. J Mol Biol 387:1061–1066. https://doi.org/10.1016/j.jmb.2009.02.033
doi: 10.1016/j.jmb.2009.02.033
pubmed: 19236877